



**May 20, 2026**

**BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Scrip Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Newspaper Advertisement - Audited Financial Results of the Company for the quarter and financial year ended on March 31, 2026**

Pursuant to Regulations 30, 47 and 52(8) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of the newspaper advertisement of the Audited Financial Results of the Company for the quarter and financial year ended on March 31, 2026 as published in "Financial Express" and "Jansatta" on May 20, 2026.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Hitesh Kumar Jain**  
**Company Secretary &**  
**Compliance Officer**

Encl.: A/a

# NEPHROCARE HEALTH SERVICES LIMITED

(formerly Nephrocare Health Services Private Limited)

CIN:L85100TG2009PLC066359

Regd. Off: 5th Floor, D Block, iLabs Centre, Plot 18, Software Units Layout, Sy. No. 64, Madhapur, Shaikpet, Hyderabad, Telangana, India - 500081; Tel: +91 40 4240 8039 | cs@nephroplus.com | www.nephroplus.com

## AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND FINANCIAL YEAR ENDED MARCH 31, 2026

The Audited Standalone and Consolidated Financial Results of the Company for the quarter and Financial year ended March 31, 2026, as approved by the Board of Directors of the Company in its meeting held on May 19, 2026 and as filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Audit Report thereon issued by the Statutory Auditors of the Company, are available on the website of the stock exchanges ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)), and Company webpage, <https://nephroplus.com/investors>. The said results can also be accessed by scanning the following Quick Response Code.



By order of the Board of Directors  
For Nephrocare Health Services Limited  
(Formerly Nephrocare Health Services Private Limited)

Sd/-  
Kishore Kathri  
Company Secretary  
ICSI M.No. F9895

Date: 19-05-2026  
Place: Hyderabad

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

### PUBLIC ANNOUNCEMENT



(Please Scan this QR Code to view DRHP & Draft Abridged Prospectus)

# LAPL AUTOMOTIVE LIMITED

(Formerly known as LAPL Automotive Private Limited)

CORPORATE IDENTITY NUMBER: U34300MH2004PLC149728

Our Company was originally incorporated as 'LAPL Automotive Private Limited' a private limited company under the Companies Act, 1956 at Maharashtra, Mumbai, pursuant to a certificate of incorporation dated November 13, 2004 issued by the Registrar of Companies, Maharashtra, Mumbai. Thereafter, name of our Company was changed from 'LAPL Automotive Private Limited' to 'LAPL Automotive Limited', consequent to conversion of our Company from private to public company, pursuant to a special resolution passed by the shareholders of our Company on December 02, 2024 and a fresh certificate of incorporation consequent to conversion of the company was issued by the Central Processing Centre on December 13, 2024. Our Company's Corporate Identity Number is U34300MH2004PLC149728. For details of change in administration of our Company, please refer to the chapter titled "History and Certain Corporate Matters" on page 163 of the Draft Red Herring Prospectus.

Registered Office: Plot No. 90, Sector No. 05, Auric City, Shendra Industrial Area, Chikalthana Industrial Area, Aurangabad, Maharashtra, India. 431006

Tel: +91 8378994623; E-mail id: [group.cs@laplautomotive.com](mailto:group.cs@laplautomotive.com);

Investor Grievance Mail id: [investor.grievance@laplautomotive.com](mailto:investor.grievance@laplautomotive.com); Website: <https://www.laplautomotive.com/>;

Contact Person: Ms. Shubhangi Madhukar Rajput, Company Secretary and Compliance Officer;

**OUR PROMOTERS: MR. NEERAJ SATYAPRAKASH GOYAL, MR. SHUBHAM NEERAJ GOYAL AND MRS. ANITA NEERAJ GOYAL**

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BOMBAY STOCK EXCHANGE ("BSE")."

### THE ISSUE

INITIAL PUBLIC ISSUE OF UP TO 36,00,000 EQUITY SHARES OF FACE VALUE ₹ 10/- EACH (THE "EQUITY SHARES") OF LAPL AUTOMOTIVE LIMITED ("OUR COMPANY" OR "LAPL" OR THE "ISSUER") FOR CASH AT AN ISSUE PRICE OF ₹ [ ] PER EQUITY SHARE (INCLUDING A SECURITIES PREMIUM OF ₹ [ ] PER EQUITY SHARE) ("ISSUE PRICE"), AGGREGATING UP TO ₹ [ ] LAKHS (THE "ISSUE") OF WHICH UP TO [ ] EQUITY SHARES AGGREGATING TO ₹ [ ] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF UP TO [ ] EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT AN ISSUE PRICE OF ₹ [ ] PER EQUITY SHARE AGGREGATING UP TO ₹ [ ] LAKHS IS HEREAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE UP TO [ ] % AND UP TO [ ] % RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF EQUITY SHARES IS ₹ 10/- EACH. THE ISSUE PRICE IS [ ] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGER AND WILL BE ADVERTISED IN ALL EDITIONS OF [ ] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER), ALL EDITIONS OF [ ] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER) AND ALL EDITIONS OF [ ] (A WIDELY CIRCULATED MARATHI NATIONAL DAILY NEWSPAPER (MARATHI BEING THE REGIONAL LANGUAGE, WHERE THE REGISTERED OFFICE OF THE COMPANY IS SITUATED) AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF BSE ("BSE SME") FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE.

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company may, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of three Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank as applicable.

This Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (the "SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 (1) and 253 (2) of the SEBI ICDR Regulations 2018, wherein not more than 50.00% of the Net Issue shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company in consultation with the BRLMs may allocate up to 60.00% of the QIB Portion to Anchor Investors on a discretionary basis ("Anchor Investor Portion"). One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price in accordance with the SEBI ICDR Regulations. However, with effect from December 01, 2025, pursuant to the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) (Third Amendment) Regulations, 2025, of which, up to 40% of the Anchor Investor Portion shall be reserved in the following manner: (i) 33.33% shall be available for allocation to domestic Mutual Funds and (ii) 6.67% shall be available for allocation to life insurance companies and pension funds, subject to valid Bids being received from domestic Mutual Funds, life insurance companies, and pension funds at or above the Anchor Investor Allocation Price. In the event of under-subscription under (i) above, the allocation may be made to domestic Mutual Funds. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the remaining QIB Portion (other than the Anchor Investor Portion) ("Net QIB Portion"). Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, other than Anchor Investors, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, the SEBI ICDR Regulations 2018, states that not less than 35% of the Net Issue shall be available for allocation to Individual Investors who applies for minimum application size. Not less than 15% of the Net Issue shall be available for allocation to Non-Institutional Investors of which one-third of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than two lots and up to such lots as equivalent to not more than ₹ 10.00 Lakhs and two-thirds of the Non-Institutional Portion will be available for allocation to Bidders with an application size of more than ₹ 10.00 Lakhs and under-subscription in either of these two sub-categories of Non-Institutional Portion may be allocated to Bidders in the other subcategory of Non-Institutional Portion. Subject to the availability of shares in non-institutional investors' category, the allotment to each Non-Institutional Investor shall not be less than the minimum application size in Non-Institutional Category and the remaining available Equity Shares, if any, shall be allocated on a proportionate basis in accordance with the conditions specified in this regard in Schedule XIII of the SEBI (ICDR) Regulations, 2018. All Potential Bidders, other than Anchor Investors, are required to participate in the Issue by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self-Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, please refer to the chapter titled "Issue Procedure" on page 246 of the Draft Red Herring Prospectus.

This public announcement is being made in compliance with the Regulation 247 of SEBI (ICDR) Regulations, 2018 and SEBI (ICDR) (Amendment) Regulations, 2025 vide notification dated March 03, 2025, and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME companies to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake initial public offering of its Equity Shares pursuant to the Issue and DRHP dated May 18, 2026 which has been filed with the SME Platform of BSE Limited. Pursuant to SEBI (ICDR) (Amendment) Regulations, 2025 on March 03, 2025 and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME companies, for fulfilling all additional eligibility criteria, the DRHP filed with the SME Platform of BSE Limited (BSE SME) shall be made available to the public for comments, if any, for a period of at least 21 days, from the date of such filing by hosting it on the website of the BSE at <https://www.bseindia.com/> and the website of the Company at <https://www.laplautomotive.com/> and at the website of BRLM i.e. GYR Capital Advisors Private Limited at <https://gyrcapitaladvisors.com>. Our Company hereby invites the members of the public to give their comments on the DRHP filed with the SME Platform of BSE Limited (BSE SME) with respect to disclosures made in DRHP. The members of the public are requested to send a copy of their comments to Stock Exchange, to Company Secretary and Compliance Officer of our Company and/or the BRLM at their respective addresses mentioned below. All comments must be received by BSE, and/or our Company and/or Company Secretary and Compliance Officer of our Company and/or the BRLM in relation to the issue on or before 5 p.m. on the 21<sup>st</sup> day from the aforesaid date of filing the DRHP with BSE SME.

Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of investors is invited to the section titled "Risk Factors" beginning on Page No. 22 of the Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on SME Platform of BSE ("BSE SME"). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see "Capital Structure" beginning on page 60 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, please refer "Our History and Certain Corporate Matters" beginning on page 163 of the Draft Red Herring Prospectus.

BOOK RUNNING LEAD MANAGERS	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 <b>GYR Capital Advisors Private Limited</b> SEBI Registration Number: INM000012810 Address: 428, Gala Empire, Near JB Tower, Drive in Road, Thaltej, Ahmedabad-380 054, Gujarat, India. Telephone No: +91 87775 64648 Website: <a href="http://www.gyrcapitaladvisors.com">www.gyrcapitaladvisors.com</a> Email ID: <a href="mailto:laplautomotive ipo@gyrcapitaladvisors.in">laplautomotive ipo@gyrcapitaladvisors.in</a> Contact Person: Mr. Mohit Baid	 <b>Maashitla Securities Private Limited</b> SEBI Registration No.: INR000004370 Address: 451, Krishna Apra Business Square, Netaji Subhash Place, Pitampura, New Delhi-110034, India. Telephone No: 011-47581432 Email: <a href="mailto:investor.ipo@maashitla.com">investor.ipo@maashitla.com</a> Website: <a href="http://www.maashitla.com">www.maashitla.com</a> Contact Person: Mr. Mukul Agarwal	 <b>Ms. Shubhangi Madhukar Rajput</b> Address: Plot No. 90, Sector No. 05, Auric City, Shendra Industrial Area, Chikalthana Industrial Area, Aurangabad, Maharashtra, India, 431006 Tel.: +91 83789 94623 E-mail: <a href="mailto:group.cs@laplautomotive.com">group.cs@laplautomotive.com</a> Website: <a href="https://www.laplautomotive.com/">https://www.laplautomotive.com/</a> Investors can contact our Company Secretary and Compliance Officer, the Book Running Lead Managers or the Registrar to the Issue, in case of any pre-issue or post-issue related problems, such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders and non-receipt of funds by electronic mode etc.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

FOR LAPL AUTOMOTIVE LIMITED ON BEHALF OF THE BOARD OF DIRECTORS

Sd/-  
Ms. Shubhangi Madhukar Rajput  
COMPANY SECRETARY AND COMPLIANCE OFFICER

DATE: May 19, 2026  
PLACE: Aurangabad

Disclaimer: LAPL AUTOMOTIVE LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public issue of its Equity Shares and has filed the Draft Red Herring Prospectus on May 18, 2026. The Draft Red Herring Prospectus is available on the website of BSE SME at <https://www.bseindia.com/> and is available on the websites of the BRLM at <https://gyrcapitaladvisors.com/offer-documents/> and also on the website of the Company <https://www.laplautomotive.com/>. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see section titled "Risk Factors" beginning on page 22 of the Draft Red Herring Prospectus. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulations under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

# BEML Land Assets Limited



(CIN: L70109KA2021GOI149486), Schedule 'C' Company under Ministry of Defence, Govt. of India  
Registered Office: "BEML SOUDHA", 23/1, 4th Main Road, S.R. Nagar, Bengaluru-560 027.  
Tel. & Fax: (080) 22963140, E-mail: [cs@blal.in](mailto:cs@blal.in), Website: [www.blal.in](http://www.blal.in)

## AUDITED FINANCIAL RESULTS FOR THE 04TH QUARTER AND FINANCIAL YEAR ENDED 31-03-2026

The Board of Directors of BEML Land Assets Limited (BLAL) at the meeting held on 18-05-2026 approved the audited Financial Results for the 04th Quarter and year ended 31-03-2026.

The full format of the aforesaid results along with the Audit Report thereon, as filed with BSE and NSE, is available on the websites of BSE at [www.bseindia.com](http://www.bseindia.com), NSE at [www.nseindia.com](http://www.nseindia.com), and Company's website at [www.blal.in](http://www.blal.in).

The results can also be accessed by scanning Quick Response (QR) Code provided below:



Date: 18.05.2026  
Place: Bengaluru

By order of the Board  
for BEML Land Assets Limited  
Sd/-  
**SHANTANU ROY**  
Chairman and Managing Director  
DIN: 10053283

# NORICAN DISA INDIA LIMITED

Shaping Industry

Regd. Office: World Trade Center, 6th Floor, Unit No. S-604 Brigade Gateway Campus, 26/1, Dr. Rajkumar Road, Malleswaram-Rajajinagar, Bangalore - 560055. Tel : +91 80 22496700. Fax : +91 80 2249 6750. E-mail: [bangalore@noricane.com](mailto:bangalore@noricane.com), [www.disa-india.com](http://www.disa-india.com)  
CIN No: L85110KA1984PLC006116

## EXTRACT OF FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026

(Rs. in Million)

Particulars	Standalone			Consolidated		
	3 months ended	Year Ended	Corresponding 3 months ended in the previous year	3 months ended	Year Ended	Corresponding 3 months ended in the previous year
	31.03.2026	31.03.2026	31.03.2025	31.03.2026	31.03.2026	31.03.2025
	Audited	Audited	Audited	Audited	Audited	Audited
Revenue from Operations	908.1	4,247.0	1,077.8	908.1	4,251.0	1,083.3
Net Profit / (Loss) for the period (Before tax, Exceptional and/or Extraordinary items)	179.2	761.9	221.9	179.8	758.9	220.0
Net Profit / (Loss) for the period (Before tax, after Exceptional and/or Extraordinary items)	179.2	726.8	221.9	179.8	723.8	178.1
Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	131.2	539.2	166.9	131.8	536.2	127.2
Total Comprehensive Income for the period [Comprising profit / (Loss) for the period (after tax) and other comprehensive income (after tax)]	125.6	533.3	158.9	126.2	530.3	119.4
Equity Share Capital	14.5	14.5	14.5	14.5	14.5	14.5
Other Equity (excluding Revaluation reserve as shown in the Audited Balance Sheet as on year end)	—	3,004.7	—	—	3,036.9	—
Earnings Per Share (Face Value of Rs. 10/- each)						
Basic -Rs.	90.22	370.79	114.77	90.63	368.72	87.47
Diluted -Rs.	90.22	370.79	114.77	90.63	368.72	87.47

Notes:

The above Quarterly financial results is an extract of the detailed format of Quarter / Year ended audited financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarter / Year ended financial results are available on the Stock Exchange website [www.bseindia.com](http://www.bseindia.com) and on the company website [www.disa-india.com](http://www.disa-india.com).



Place : Bengaluru  
Date : May 19, 2026

For DISA India Limited  
Lokesh Saxena  
Managing Director



# MANKIND PHARMA LIMITED

Registered Office: 208, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; Tel.: +91 11 4747 6600  
Corporate Office: 262, Okhla Industrial Estate, Phase-III, New Delhi - 110 020, Delhi, India; Tel.: +91 11 4684 6700  
Email: [investors@mankindpharma.com](mailto:investors@mankindpharma.com), Website: [www.mankindpharma.com](http://www.mankindpharma.com), CIN: L74899DL1991PLC044843

## EXTRACT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(₹ in Crores except as stated otherwise)

S. No.	Particulars	Consolidated				
		For the quarter ended		For the year ended		
		31.03.2026 (Audited)	31.12.2025 (Unaudited)	31.03.2025 (Audited)	31.03.2026 (Audited)	31.03.2025 (Audited)
1	Revenue from operations	3,442.93	3,567.20	3,079.37	14,277.64	12,207.44
2	Profit for the period/year before exceptional items and tax	682.33	615.59	515.43	2,462.43	2,516.33
3	Profit for the period/year after exceptional items and tax	559.42	413.88	428.99	1,938.10	2,006.59
4	Total comprehensive income for the period/ year	588.36	419.83	410.73	1,995.14	2,002.83
5	Paid up equity share capital	41.28	41.28	41.26	41.28	41.26
6	Other equity excluding revaluation reserve	N.A.	N.A.	N.A.	16,259.06	14,291.13
7	Earnings per equity share of face value of ₹ 1 each					
	- Basic EPS (in ₹)	13.44	9.90	10.30	46.35	49.17
	- Diluted EPS (in ₹)	13.41	9.89	10.29	46.28	49.08
	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)		

The key standalone financial information is as under:

(₹ in Crores except as stated otherwise)

S. No.	Particulars	For the quarter ended		For the year ended		
		31.03.2026 (Audited)	31.12.2025 (Unaudited)	31.03.2025 (Audited)	31.03.2026 (Audited)	31.03.2025 (Audited)
		1	Revenue from operations	2,581.82	2,632.68	2,119.46
2	Profit for the period/year before exceptional items and tax	810.83	588.71	281.45	2,421.24	2,146.50
3	Profit for the period/year after exceptional items and tax	713.61	448.88	235.16	2,037.56	1,724.76
4	Total comprehensive income for the period/year	722.32	451.93	232.06	2,066.17	1,791.14
5	Net worth (₹ Crores)	16,396.94	15,734.34	14,322.72	16,396.94	14,322.72
6	Debt equity ratio (times)	0.34	0.40	0.52	0.34	0.52
7	Debt service coverage ratio (times)	0.79	0.22	0.18	0.52	0.53
8	Interest service coverage ratio (times)	6.28	4.24	1.38	4.54	5.39

Notes:

- The above is an extract of the detailed format of audited Consolidated and Standalone Financial Results for the quarter and year ended March 31, 2026 filed with the Stock Exchanges under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the above Financial Results are available on the Stock Exchanges website: [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) and also on the Company's website: [www.mankindpharma.com](http://www.mankindpharma.com). Full Financial Results can also be accessed by scanning the QR code given hereunder.
- The audited Consolidated and Standalone Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on May 19, 2026.
- The above audited Consolidated and Standalone Financial Information is for continuing operations. Refer full format of the Quarterly Financial Results for discontinued operations.



Place: New Delhi  
Date: May 19, 2026

For and on behalf of

MANKIND PHARMA LIMITED

Sd/-  
Rajeev Juneja  
Vice Chairman and Managing Director  
DIN : 00283481

